A study to evaluate mirabegron in pediatric participants from 5 to less than 18 years of age with overactive bladder (OAB)

Trial Identifier: 178-CL-204
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: March 2021
Primary Completion Date: July 2023
Study Completion Date: July 2023
Condition: Bladder Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Korea (Republic of), Gyeongsangnamdo Yangsan-Si, Gyeongsangnamdo, Korea (Republic of), 50612
MEXICO Ciudad de Mexico, MEXICO
MEXICO Nuevo León, MEXICO
Russian Federation, Moskva Moscow, Moskva, Russian Federation, 117997
Russian Federation, Tatarstan, Respublika Kazan, Tatarstan, Respublika, Russian Federation, 420138
Turkey, Bursa Bursa, Turkey, 16059